Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

The latest announcement is out from Septerna, Inc. ( (SEPN) ).

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed.

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic collaborations, despite challenges in the US market.

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

Under the agreement, Novo Nordisk will pay more than $200 million up front, with Septerna eligible to receive up to $2.2 billion based on development.

Investing.com -- Septerna, Inc. (NASDAQ: SEPN ), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, saw its shares fall 4.3% after reporting a widened net loss for ...

Novo Nordisk signed a licensing deal with Septerna to co-develop oral therapies targeting GLP-1, GIP, and glucagon receptors for treating obesity, type II diabetes and other cardiometabolic diseases.